Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-18

Clinical Trial Update: Neoadjuvant Pembrolizumab [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of pembrolizumab in non-small cell lung cancer has completed. Results were posted on 2020-02-18.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Neal Ready MD PhD | Conditions: Non-small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-18